Comparison of QR678® as monotherapy and as combination formula with 5% Minoxidil solution and oral Finasteride in the clinical assessment of male androgenetic alopecia
Background and Scientific Context
Androgenetic alopecia (AGA) is a commonly encountered form of patterned hair loss, characterized by progressive follicular miniaturization and alterations in hair cycle dynamics. In routine dermatology practice, topical minoxidil and oral finasteride are frequently used as part of long-term management strategies. Despite widespread use, clinical responses to these agents may vary, and a proportion of patients continue to experience ongoing hair thinning or hair shedding over time.
This has led clinicians to explore adjunctive approaches used alongside established therapies. Combination-based clinical evaluations provide an opportunity to document hair and scalp parameters when more than one modality is employed concurrently. This study documents clinical observations recorded in patients with androgenetic alopecia receiving QR678 alongside topical minoxidil, without attributing causality or therapeutic effect to either intervention.
Study Design and Methodology
The study was conducted as a prospective clinical evaluation involving male and female patients diagnosed with androgenetic alopecia using standard clinical classification systems. Participants were enrolled based on predefined inclusion criteria and were already using topical minoxidil as part of their routine hair care regimen.
QR678 was administered via localized intradermal scalp application at predefined intervals under dermatological supervision. The study followed an open-label design and did not include randomization, placebo control, or comparator arms. Baseline assessments were performed prior to initiation of combination use, with subsequent evaluations conducted at regular intervals over the observation period.
The primary objective of the study was to document hair and scalp parameters observed during concurrent use of minoxidil and QR678 under routine clinical conditions, rather than to assess therapeutic efficacy or treatment outcomes.
Assessment Parameters
Clinical documentation was performed using commonly employed dermatological assessment tools, including:
- Hair pull testing to record active hair shedding at the time of examination
- Videomicroscopic evaluation to document hair density, hair shaft characteristics, and follicular distribution
- Global photographic assessment to visually record scalp appearance across defined regions
- Patient-reported observations captured through structured clinical interactions
These parameters were used descriptively to support longitudinal documentation across study visits.
Observational Findings
Across successive evaluations, clinicians recorded changes noted in hair shedding patterns, hair density distribution, and hair shaft appearance. Observations were documented without assigning causality to any single component of the combination regimen.
Videomicroscopic and photographic documentation provided visual records of hair and scalp parameters at different time points. These records were used for within-patient comparison over time and were interpreted within the known variability associated with hair cycle phases and individual biological differences.
Patient-reported observations reflected individual perceptions of hair appearance and shedding during the observation period. These reports were recorded descriptively and were not used to draw conclusions regarding effectiveness or comparative benefit.
Safety and Tolerability Observations
Tolerability was monitored throughout the study duration. Reported observations were limited to mild and transient localized scalp sensations associated with intradermal application. No systemic adverse events were reported during the observation period.
Concurrent use of topical minoxidil did not result in additional tolerability concerns within the scope of clinical documentation. No participants discontinued the study due to safety-related reasons.
Scope, Limitations, and Research Relevance
The study is subject to limitations inherent to observational clinical evaluations, including lack of control groups, absence of blinding, and reliance on descriptive documentation. The study does not establish therapeutic efficacy, additive benefit, or superiority of combination use over monotherapy.
Within these limitations, the paper contributes structured clinical documentation of hair and scalp parameters observed during concurrent use of minoxidil and QR678 in patients with androgenetic alopecia. The findings may serve as reference material for clinicians reviewing combination-based approaches in routine practice and may inform the design of future controlled investigations.
Correspondence
Dr. Debraj Shome,
Director & Consultant Facial Plastic Surgeon,
The Esthetic Clinics, | Kandivali, Mumbai, India
Email: debraj.shome@theestheticclinic.com
ORCID
Debraj Shome https://orcid.org/0000-0003-2163-1170
Disclaimer:
The research papers and clinical articles referenced on this website are peer-reviewed scientific publications authored by qualified medical professionals and represent the observations and conclusions of the respective authors, based on their individual clinical research.
These clinical references are provided for informational and educational purposes and should not be interpreted as promotional claims or outcome guarantees by QR678®. Consumers are advised to consult a qualified healthcare professional for medical interpretation or hair- or scalp-related concerns.
QR678®: SCIENCE Backed Research & Development Proprietary Product Technology
The QR678® research & development platform technology is a proprietary first-in-class technology. This science backed technology is giving rise to multiple products that arrest hair fall and address the thickness, density of hair follicles leading to greater coverage in hair loss. This R&D technology deals with multiple human hair growth related growth factors that are naturally present in our scalp making products derived from these completely natural. Research on this platform technology has resulted in this being awarded USA & Indian patents and has led to over 16+ clinical research papers being published with products derived from this unique technology. The hair growth factors penetrate deep into the scalp and provide nourishment to the scale. Unlike other treatments that contains harmful medication, products derived from QR678® are almost completely devoid of side effects.
HOW DOES IT WORK?
Benefits of choosing QR678®
QR678® ADVANTAGES
(Derived From Plants)
Quick & Effective (Single
Session in 10 Minutes)
Non Surgical
Success Rate
13+ Published Researched Clinical Trials Demonstrating Efficacy
LIFE CHANGING RESULTS
PRE TREATMENT
POST 6 SESSIONS
PRE TREATMENT
POST 6 SESSIONS
PRE TREATMENT
POST 6 SESSIONS
25 year old female from alopecia areata, was also diagnosed with hypothyroid. She achieved impressive results with QR678, a completely steroid-off treatment.
PRE TREATMENT
POST 6 SESSIONS
39 year old male suffering from male pattern hair loss for 15 years gained a significant amount of hair with QR678
MEDIA INTERVIEWS
TESTIMONIALS
HIGHLIGHTS IN MEDICAL CONFERENCES
CUTICON – December 2023
Dazzling moments at Cuticon 2023, Gujarat! QR678 took centre stage, earning accolades from top medical professionals.
QR678 made it’s presence felt at FADS (Face Aesthetics Dermatologists Society), the 7th International Conference held at Goa. Renowned dermatologists got QR678 Neo administered and shared their positive experience.
QR678® drew attention with an enlightening session and live demonstration at CDCON 2022 – a platform to challenge changing practices along the lines of Exploration and Innovation.
GLOBAL PRESENCE
OUR PARTNERS
FAQ'S
How is QR678® better than other hair fall treatments?
QR678® is a mixture of natural growth factors that are already present in the scalp and therefore it is completely safe to use on everybody. It has the right concentration of specific hair growth factors and QR678® does not have any side effects, is performed as an outpatient procedure and the results are visible within eight weeks of starting the treatment. You can listen for yourself what the patients say about QR678® hair fall treatment https://www.youtube.com/watch?v=pIvjpQgSsrc
How often do I need to repeat QR678® treatment?
QR678® injections are administered in 8-12 sessions in about 3-4 weeks apart. The results are visible after few weeks. Once you have achieved the desired results the injections need not be repeated unless the hair fall starts again. This is because QR678® make the hair follicles healthy. Get to know more about why QR678® is highly effective in treating hair fall and increasing hair growth. http://www.qr678.in/
What precautions should I take after QR678® treatment?
QR678® is a completely safe treatment without side effects and you can go about your daily routine after the sessions. The only care you need to take is to use a gentle shampoo not before the next day of the treatment and avoid scratching and rubbing the treating area. If you have any other problem then consult your dermatologist. https://www.youtube.com/watch?v=LNm2z3EGLxg
Can QR678® be used after hair transplant?
Yes, using QR678® after hair transplant produces very successful results. QR678® gives faster density and reduces the catagen loss of transplanted hair. The growth factors in QR678® Neo help in faster healing and activate the dormant follicles and thus
- Increase the viability of hair follicles
- Improve healing and repairing of tissue process
- Strengthen the inactive hair follicles and stimulate hair growth
- Improves the health of existing hair and they will become fuller and stronger
QR678® can be given in multiple treatment sessions after three to four weeks after successful hair transplant surgery. QR678® can also be used before the hair transplant surgery to reduce the area of transplant and improve the results.
How is QR678® better than PRP and stem cell hair fall treatment?
QR678® is a relatively new treatment for hair fall and hair regrowth but in the short time of its invention QR678® has proven to be more effective than PRP and stem cell treatment for reducing hair fall. QR678® produces longer lasting and better results and is completely safe and without any side effects. QR678® can help treat and rogenetic alopecia, female pattern hair loss, and hair loss because of chemotherapy, seborrheic dermatitis, and alopecia areata.
PRP and stem cell on the other hand do not have the specific concentration of required growth factors, they lack standardisation in terms of treatment protocols and preparation of the solution injected and lack good quality studies to prove their benefits. produce guaranteed results and can cause tightness and tenderness in scalp,
scar tissue formation, calcification of the injected points, and formation of scar tissues. Both processes are still under investigation and their results are still awaiting confirmation. Dr Rinky Kapoor of The Esthetic Clinics explains the difference between QR678® and stem cell here: https://www.youtube.com/watch?v=wgNihm8ciu4 and
Can genetic hair loss be treated?
Yes genetic hair loss can be treated if the treatment is started in time. Heredity hair loss usually runs in the family and can affect both men and women. If you too have a close elder relative who lost his or hair in a patterned baldness then you should keep a close eye on your hair too. Hereditary hair loss usually happens in a pattern; M or W shaped in men and along the hair part in women. See the doctor immediately if you suffer from hair loss. There are many common and successful treatments available for genetic hair loss which include
- Topical and oral medications: These include Minoxidil topical lotion and Finasteride tablets.
- Hair transplantation using FUT and FUE methods.
- Nutritional supplements: Your physician might also suggest some hair supplements that can help arrest hair fall. Dietary supplements containing Vitamin A, C, and Biotin, zinc, and iron can also help control hair fall caused because of genetics.
Treatment option for Chemotherapy induced Alopecia?
Alopecia post chemotherapy is a very common consequence of cancer treatments and therapies and it is often the most psychologically and socially devastating side effect. Many patients shy away from the treatments because of fear of hair fall and hair loss. However, in most cases, such alopecia is reversible but the recovery takes several months and even up to a year. Some basic latest treatment methods will speed up the healing:
- Scalp Cooling: This is a FDA approved method for patients suffering from breast cancer. Scalp cooling or hypothermia results in constriction of the blood vessels in the scalp, which in turn leads to reduced delivery of chemotherapy to the hair. Scalp cooling devices consist of cooling unit that circulate the coolant on the scalp. This is done about 30 minutes before the start of chemotherapy. Patients can feel some mild discomfort, nausea, and dry skin because of scalp cooling.
- Topical Minoxidil: Minoxidil helps by increasing the blood flow to the hair follicle thereby preventing miniaturization of hair follicle.
- QR678® hair regrowth treatment: QR678® is a FDA approved, completely safe hair regrowth treatment that has no side effects or causes any discomfort to the patient. Clinical trials have proved QR678 to be effective in treatment of chemotherapy induced alopecia in both men and women. The results of QR678® last lifelong.